11:52 AM EST - Resverlogix Corp. : announced two additional results from the ongoing analysis of its Phase 2b ASSURE clinical trial using intravascular ultrasound (IVUS) to study high-risk cardiovascular disease (CVD) patients for assessing benefits of RVX-208. This lead molecule is a member of a new class of compounds that affects cellular epigenetics by specifically inhibiting a BET protein leading to enhanced apoA-I gene transcription and the creation of functional HDL particles for treating atherosclerotic CVD. Since the completion of the ASSURE trial the continued analysis of the data have yielded two new findings that detail the effects of RVX-208 on vascular inflammation and virtual histology. Resverlogix Corp.
shares T.RVX are trading up $0.09 at $0.66.
